Cytoreductive approach to peritoneal carcinomatosis from adenocarcinoma of the large bowel (Report of 8 cases)

We aimed to present our clinical experience for the treatment of peritoneal carcinomatosis from large bowel carcinoma. Eight patients with peritoneal carcinamatosis from colorectal carcinoma had cytoreductive therapy. There were 4 men, 4 women ranging in age 23 to 75 years (mean 51 yrs.). The treatment included cytoreductive surgery, early postoperative intraperitoneal chemotherapy and late postoperative systemic chemotherapy. Mean survival oft he patients was 11.6 months. Six (75 %) out of 8 patients were alive. Two (25 %) patients died of disease. Although it is small series cytoreductive approach seems to have some benefits for the patients

Retroperitoneal fibrosis mimicking a rectal tumor - Report of a case

PURPOSE: The study contained herein was undertaken to report an original case of retroperitoneal fibrosis that resembled a rectal tumor both symptomatically and radiologically. METHOD: Reported is a case of retrorectal fibrosis with a brief Literature review of the topic. RESULT: Although many forms of retroperitoneal fibrosis have been reported, extension below the pelvic rim is very unusual. Compression of the rectum and right ureter, with constipation as a chief complaint, made this case presentation unusual. Although computerized tomographic findings and needle biopsies supported the diagnosis of retroperitoneal fibrosis, an exploratory laparotomy was necessary to rule out a malignancy and to release the ureter. CONCLUSION: A fibrotic mass involving the retrorectal region may mimic a rectal tumor. To reach a final diagnosis, an exploratory laparotomp may be necessary, despite sophisticated evaluation techniques, because it is difficult to differentiate whether the mass is malignant

Brentuximab Vedotin For Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report the experience with brentuximab vedotin as single agent in 58 patients with relapsed or refractory Hodgkin lymphoma. The objective response rate was 63.5 % with 13 complete responders (26.5 %) among 49 patients evaluated at the early phase of treatment (2–5 cycles). Upon treatment prolongation (≥6 cycles), 37 patients achieved a final objective response rate of 32.4 % with 21.6 % of complete and 10.8 % of partial response. Overall survival at 12 months was 70.6 %, and progression-free survival at 12 months was 32.8 %. Median overall survival could not be reached and median progression-free survival was 7 months. While the median duration of response was 9 months in the whole cohort, it was 11.5 months in the complete responders. Complete response rates in patients treated with >3 chemotherapy regimens before brentuximab vedotin were significantly lower (p = 0.016). Fourteen patients were subsequently transplanted. In conclusion, brentuximab vedotin provided a bridge to transplantation in approximately one quarter of the patients. The declining response rates during the course of treatment suggest that transplantation should be implemented early during brentuximab vedotin treatment.PubMedWoSScopu